Table 1.
Characteristics of the population (n=39) and targets of Phase I trial drug administered.
|
ECOG Performance Status
| ||
| 0 | 17 | |
| 1 | 22 | |
|
| ||
|
Gender
| ||
| Male | 18 | |
| Female | 21 | |
|
| ||
|
Histology
| ||
| Colorectal cancer | 12 | |
| Ovarian cancer | 9 | |
| Breast cancer | 7 | |
| Bladder cancer | 3 | |
| Glioblastoma | 2 | |
| Lung cancer adenocarcinoma | 2 | |
| Endometrial cancer | 1 | |
| Renal cell cancer | 1 | |
| Penile cancer | 1 | |
| Melanoma | 1 | |
|
| ||
|
Previous treatment
| ||
| Chemotherapy | 38 | |
| Median lines of treatment (Range) | 2 [0-8] | |
| Radiotherapy | 15 | |
| Hormonal therapy | 4 | |
|
| ||
|
Phase I trials targets
| ||
| PI3K-AKT-MTOR pathway | ||
| PI3K inhibitor | 10 | |
| PI3K inhibitor + MEK inhibitor ( | 4 | |
| TOR kinase inhibitor | 8 | |
| TOR kinase inhibitor + Taxane | 3 | |
| AKT inhibitor | 3 | |
| MEK pathway | ||
| MEK inhibitor + IGF-IR inhibitor | 5 | |
| MEK/RAF inhibitor | 2 | |
| Other | ||
| PARP inhibitor | 2 | |
| PIM kinase inhibitor | 2 | |
| Analog of Oleic Acid | 2 | |
| Androgen receptor inhibitor | 1 | |
| AGC kinase inhibitor | 1 | |
| Folate inhibitor | 1 | |